Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



What Should Investors Think About Solazyme's Debt Offering and Manufacturing Plans?

Cash may be king, but the market was in no mood to celebrate after renewable oil manufacturer Solazyme (NASDAQ: SZYM  ) registered a debt offering of up to $115 million and common stock sale of up to 5.75 million shares. The offering eclipsed news of a new product lineup, Encapso, for the oil and gas drilling services industry.

Source: Google Finance.

Investors may be perplexed as to why a company with nearly $167 million at the end of 2013, and entering the ramp-up phase for its first two commercial scale facilities in Clinton, Iowa and Moema, Brazil, would need to suddenly add up to $200 million to the coffers. What will the cash fund? Should you expect delays at Moema?

Why raise cash now?
Solazyme management has done an excellent job in guiding operations to success thus far and not overpromising the potential of its technology platform. Aside from capturing development partnerships, purchase agreements, and supply contracts with multiple partners in multiple markets, management has carefully choreographed announcements and business updates. For instance, the last debt offering of $115 million was announced simultaneously with the award of a $120 million loan (now just $108 million thanks to inflation) from the Brazil Development Bank, or BNDES. Announcing the launch of a new and unproven product line may not carry the same weight as the BNDES loan, but the field success of Encapso makes its future potential quite compelling.

So, why raise cash now? Solazyme is simply taking advantage of current market conditions -- and a relatively lofty share price -- to further bolster its balance sheet. The company could raise gross proceeds of $180 million, assuming overallotment of both debt notes and common stock, which would give the company roughly $300 million in cash at the end of the first quarter of 2014. Sure, you could make the argument that shares will go higher with future announcements, progress, and growing revenue, but we have no idea what discussions management has entered into behind closed doors. Perhaps it wants to wrestle more favorable terms for expanding its manufacturing capacity with a feedstock supplier. After all, another $180 million in cash provides a bit more bargaining power.

Manufacturing plans
Management has not been shy about its intentions to pursue additional capacity from the combined 120,000 MT of annual nameplate capacity of Clinton and Moema. Solazyme has up to 200,000 MT of additional capacity penciled into its joint-venture with Brazilian sugarcane supplier Bunge (either at Moema, new global sites, or some combination of the two) and a similar agreement with Archer Daniels Midland to expand Clinton to 40,000 MT and then 100,000 MT. Moreover, there are additional opportunities for expansion, such as acquisitions of an existing facility (a brownfield site) with permits and licensing in place or co-location agreements for new facilities (a greenfield site) with outside feedstock suppliers. The debt offering should be viewed as a springboard, not a cinderblock.

Is Moema delayed?
I would not conclude that Moema is delayed because the company decided to raise cash now rather than later. In my mind, raising cash for manufacturing expansion and bringing the final pieces of equipment at Moema online for ramp-up are completely separate issues. Besides, management has already admitted that while fermentation (production of saleable product) is expected to begin in March, downstream processing will not be ready until April.

Source: Solazyme.

Utilities? Check. Quality control labs, media preparation, and automated compliance systems? Check. Seed trains (the small bioreactors that grow the cells used in production to the correct concentration before transfer to the production bioreactors) and production bioreactors of 625,000 liter volumes? Check (any day now). Downstream processing? Awaiting the results of commissioning.

I will float one idea out there. There is a chance the company is running into minor problems with its recovery equipment at Moema. Remember, the downstream processing of Clinton is conducted many miles away at a third-party site operated by American Natural Products in Galva, and prior processing has been conducted at other third-party or partnered refining sites. Thus, Solazyme may not have direct (or as much) experience with that part of the process. If that is the case, it would only result in a short-term delay without long-term implications, although the effects to 2014 revenue would be unclear at this point. It would not be a major reason to worry, however, assuming the hypothetical delay is just a minor delay to get things right.

Foolish bottom line
Dilution is never a good thing, but Solazyme is in a pretty enviable position to raise much needed capital for future expansion on relatively favorable terms. It would be much worse if the company had to raise cash to fund basic operations after running into major production problems, which is clearly not the case. The market may not like it, and shares could fall further from here for various reasons, or if Moema is delayed, but the long-term vision of Solazyme remains in place. The company will be a steal at $1 billion, assuming all goes right from here on out.

Three stocks to own for the rest of your life
As every savvy investor knows, Warren Buffett didn't make billions by betting on half-baked stocks. He isolated his best few ideas, bet big, and rode them to riches, hardly ever selling. You deserve the same. That's why our CEO, legendary investor Tom Gardner, has allowed us to reveal The Motley Fool's 3 Stocks to Own Forever. These picks are free today! Just click here now to uncover the three companies we love. 

Read/Post Comments (9) | Recommend This Article (10)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 27, 2014, at 12:20 PM, blizz83 wrote:

    There was a lot of additional information not provided to the general public in the follow-on offering roadshow presentation. Encapso video + Encapso/AlgaVia target margins and in some cases ASPs. From the tone of the call - it appears they will focus these funds to rapidly commercialize their oil field services business. How they go about doing that is anyone's guess - expansion at Clinton? New facility with new manufacturing partner? There's a lot here - you don't need to 'float' ideas just do some digging.

  • Report this Comment On March 27, 2014, at 12:44 PM, TMFBlacknGold wrote:


    "you don't need to 'float' ideas"

    Assuming the company just raised $180+ million to commercialize a single product line seems like a floated idea to me...

    We will patiently await the news on Moema in the meantime.


  • Report this Comment On March 27, 2014, at 2:55 PM, blizz83 wrote:

    It's not my idea. Came straight out of Wolfson's mouth.

  • Report this Comment On March 27, 2014, at 4:04 PM, TMFBlacknGold wrote:


    First, I stated that the debt offering and Moema were not connected. Not sure why that ruffled your feathers for your first comment.

    Second, I don't think all $180 million will go to commercializing Encapso.

    Third, even in the unlikely event that it does, the information (for which you have not provided a link) was not available at the time of writing. I won't criticize your reading comprehension skills if you don't criticize my research abilities. Deal?



  • Report this Comment On March 27, 2014, at 5:07 PM, blizz83 wrote:


    I didn't know my feathers were ruffled. I never got the sense you actually believed it had anything to do with the status of Moema. I'm not criticizing your research abilities, I just don't see anything we don't already know except for a touch of pure speculation. Perhaps, it's a bit unfair of me to say what I said if you hadn't seen the full presentation by Jonathan and Tyler, but whatever. You'll get over it.

    I don't believe they will use all $180 million for that either, but they did show on one of the slides they plan to "rapidly commercialize Encapso". I'd provide a link, but it had been removed as of my first post.

    Here's a link to their Encapso presentation video, but I can't find the prospectus...



  • Report this Comment On March 27, 2014, at 5:09 PM, blizz83 wrote:

    That should be "com" not "co" in the link.

  • Report this Comment On March 27, 2014, at 6:28 PM, ecreature wrote:

    When I learned about this new stock offering, I read that the offering was for $100 million of convertible notes and there would be a restricted stock offering of 5 million shares at $0.001 per share. The stock was selling at 13.09 at the time of the offering, so this added over $65 million to the sale of the new stock (see article on 3/25 after the market closed). Is it usual for management to give itself restricted stock equivalent to 35-40% of a new offering?

  • Report this Comment On March 28, 2014, at 2:57 PM, TMFBlacknGold wrote:


    The pricing has since been announced, and Solazyme believes it can raise net proceeds of $143.5 million from the notes (assuming over allotment) and $59.3 million from the common stock sale (assuming over allotment). The shares were priced at $11 each.

    I have not read anything about restricted stock, but the offering does include common stock. I think it's simply used as a way to mitigate debt (rather than offering an additional $60 million in notes).


  • Report this Comment On April 12, 2014, at 3:52 PM, ecrtr wrote:

    I looked further into the basis for my prior claim and found that the restricted stock would be sold at greater than $0.001. That was my earlier impression. Sorry.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2892551, ~/Articles/ArticleHandler.aspx, 8/28/2015 11:15:33 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Maxx Chatsko

Maxx has been a contributor to since 2013. He's currently a graduate student at Carnegie Mellon University merging synthetic biology with materials science & engineering. His primary coverage for TMF includes renewable energy, renewable fuels, and synthetic biology. Follow him on Twitter to keep pace with developments with engineering biology.

Today's Market

updated 1 hour ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:00 PM
SZYM $2.52 Up +0.14 +5.88%
Solazyme CAPS Rating: ***